Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Reduces Parallel Distribution Fees For Malta & Latvia To Improve Medicines Availability

Executive Summary

The European Medicines Agency is charging a reduced fee for parallel distribution of centrally authorized medicines to smaller EU member states under a new initiative that aims to improve the availability of medicines. Malta and Latvia have joined in, and two other member states have showed interest in the initiative, which will end in July 2018.

You may also be interested in...



EMA Extends Benefits Of Reduced Parallel Distribution Fee To Estonia, Slovenia

Estonia and Slovenia have been accepted onto an ongoing initiative by the European Medicines Agency that aims to boost the availability of centrally authorized drugs in smaller member states by charging companies a reduced fee for parallel distribution of medicines.

EMA Pilots Reduced Parallel Trade Fee To Improve Availability Of Medicines In Malta

The European Medicines Agency has launched a one-year pilot to help increase the availability of centrally authorized medicines in Malta by charging a reduced fee from companies involved in parallel distribution of medicines to the country1,2.

UK To Use COVID-19 Learnings To Speed Up Review Of Other Trials

A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel